Autologous Cd19/Cd22 Chimeric Antigen Receptor T-Cells
Recurrent B Acute Lymphoblastic Leukemia
M.D. Anderson Cancer CenterCell therapyPhase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
13 Active assets in the Recurrent B Acute Lymphoblastic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT) City of Hope Medical Center | Phase 3 | BB |
(+)-VINCRISTINE SWOG Cancer Research Network | Phase 3 | BB |
Nivolumab Assistance Publique - Hôpitaux de Paris | Phase 2 | B |
PEGFILGRASTIM University of Washington | Phase 2 | B |
Ruxolitinib Phosphate M.D. Anderson Cancer Center | Phase 2 | CCC |
View all 23 →
Same molecule, other indications
Autologous Cd19/Cd22 Chimeric Antigen Receptor T-Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →